Medicago’s COVID-19 vaccine – approved during February in Canada – is facing limited growth in the near term after the World Health Organization said it would not review the vaccine because the company is partly owned by U.S.-Swiss tobacco company Philip Morris, health experts say.
Canadian drug developer Medicago’s plant-based Covid-19 vaccine candidate – enhanced by GlaxoSmithKline’s booster – was 75.3 percent effective against the Delta variant of the virus in a late stage study, the two companies said on December 7.
GlaxoSmithKline is providing pandemic adjuvant technology to another company to bolster the chances of developing a vaccine against COVID-19.
Precision Plant Molecules (PPM) coined the term Cannamimetics to describe naturally inspired ways to access important, bioactive “minor” cannabinoids that currently manifest in existing hemp cultivars in de minimis concentrations. More effective plant-based extracts and concentrates can be formulated with these cannabinoids.
The FDA issued warning letters to two companies for illegally selling unapproved drug products that contain the herbal extract kratom.
